Atovaquone Suspension
Product Images NDC 0904-7459

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Atovaquone (NDC 0904-7459). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Atovaquone Oral Suspension 1)

FDA Label Image

Atovaquone Oral Suspension (750 mg/5 mL)

This is a description of Atovaquone Oral Suspension USP by MAJOR Pharmaceuticals. Each 5 mL (1 teaspoonful) contains 750 mg of Atovaquone USP. The usual dosage should be followed as per the package insert for full prescribing information. The product must be stored at temperatures between 15° to 25°C and should not be frozen. This unit dose package is not child-resistant and is intended for Institutional Use Only. For further details, visit www.majorpharmaceuticals.com.*

FDA Label Image

Atovaquone Oral Suspension 750 mg/ 5 mL (Atovaquone Oral Suspension 3)

This text provides information about a medication called Atovaquone Oral Suspension USP, with a concentration of 750 mg per 5 mL. It includes instructions to shake gently before using and indicates it is for institutional use only with a prescription requirement. The manufacturer is Major Pharmaceuticals based in Indianapolis, IN 46268.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.